Quick Answer
LIFECORE BIOMEDICAL, INC. \DE\ reported R&D Expense of $8.26 million for fiscal year 2025.
LIFECORE BIOMEDICAL, INC. \DE\ R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $8.26M | -3.7% |
| 2024 | $8.57M | -1.8% |
| 2023 | $8.74M | +11.4% |
| 2022 | $7.84M | +17.3% |
| 2021 | $6.68M | -11.8% |
| 2020 | $7.58M | -33.9% |
| 2019 | $11.47M | -10.4% |
| 2018 | $12.80M | +35.1% |
| 2017 | $9.47M | +31.1% |
| 2016 | $7.23M | +3.4% |
| 2015 | $6.99M | -3.0% |
| 2014 | $7.20M | -22.5% |
| 2013 | $9.29M | -3.4% |
| 2012 | $9.62M | +3.8% |
| 2011 | $9.28M | +112.7% |
| 2010 | $4.36M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.96M | — | -4.0% |
| February 28, 2025 | $2.04M | -5.8% | +6.3% |
| November 30, 2024 | $1.92M | -8.3% | -12.0% |
| August 31, 2024 | $2.19M | +1.9% | +0.7% |
| February 29, 2024 | $2.17M | -2.9% | +3.4% |
| November 30, 2023 | $2.10M | -3.6% | -2.2% |
| August 31, 2023 | $2.15M | -2.9% | -3.9% |
| February 28, 2023 | $2.23M | +11.7% | +2.6% |
- LIFECORE BIOMEDICAL, INC. \DE\ showed a decrease of -3.7% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, LIFECORE BIOMEDICAL, INC. \DE\’s r&d expense has grown by 89.4% (from $4.36 million to $8.26 million).
- The most recent figure is from LIFECORE BIOMEDICAL, INC. \DE\’s fiscal year 2025 report (Form 10-K), filed with the SEC on August 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: